Compounds of formula (I) have checkpoint kinase 1 (CHK1) inhibitory activity: wherein R1, R2, R5 and R6 are independently selected from hydrogen, hydroxy, methyl, trifluoromethyl, hydroxymethyl, methoxy, trifluoromethoxy, methylamino and dimethylamino； R3, and R4 are independently selected from hydrogen, hydroxy, C1-C3 alkyl, fluoro-(C1-C3)-alkyl, hydroxy-(C1C3)-alkyl, C1-C3 alkoxy, fluoro-(C1-C3)-alkoxy, hydroxy-(C1-C3)-alkoxy, -AIk-N(R11)&mdash；R12, -0-AIk-N(R11)&mdash；R12, &mdash；C(&boxH；O)OH, carboxy-(C1-C3)-alkyl, or &mdash；C(&boxH；O)&mdash；NH&mdash；R13； AIk is a straight or branched chain divalent C1-C6 alkylene radical； R7 and R8 are independently selected from hydrogen, hydroxy, or C1-C3 alkoxy； X is a straight chain divalent C1-C3 alkylene radical, optionally substituted on one or more carbons by R9 and/or R10； W is selected from &mdash；C(&boxH；O)&mdash；N(&mdash；R16)&mdash； or &mdash；N(&mdash；R17)&mdash；C(&boxH；O)&mdash；； Y is hydrogen, C1-C3 alkyl, C1-C3 alkoxy, or halo； and Q is selected from optionally substituted phenyl, optionally substituted cyclohexyl, or an optionally substituted 6-membered monocyclic heteroaryl ring.
